# Clinical Acceptance Sheet
## KB-16 Lab Interpretation & Trending Service

---

**Document ID**: KB16-CAT-001
**Version**: 1.0
**Classification**: Clinical Validation Document
**Regulatory Category**: Software as a Medical Device (SaMD) - Class II

---

## EXECUTIVE SUMMARY

| Field | Value |
|-------|-------|
| **Product Name** | KB-16 Lab Interpretation & Trending Service |
| **Product Version** | 1.0.0 |
| **Intended Use** | Clinical decision support for laboratory result interpretation |
| **Risk Classification** | Class II Medical Device (moderate risk) |
| **Target Users** | Licensed healthcare professionals |
| **Testing Date** | _________________ |
| **Testing Environment** | ☐ Local ☐ Docker ☐ Staging ☐ Production |

---

## CLINICAL VALIDATION MATRIX

### Phase 1: KB-8 Calculator Dependency Validation

| Test ID | Test Description | Expected Outcome | Pass/Fail | Notes |
|---------|------------------|------------------|-----------|-------|
| P1.1 | eGFR CKD-EPI 2021 (Black Male) | Cr=1.2, Age=55 → eGFR 72-78, Stage G2 | ☐ Pass ☐ Fail | |
| P1.2 | eGFR CKD-EPI 2021 (White Female) | Cr=0.9, Age=45 → eGFR 85-92, Stage G1 | ☐ Pass ☐ Fail | |
| P1.3 | Anion Gap Normal | Na=140, Cl=100, HCO3=24 → AG=16 | ☐ Pass ☐ Fail | |
| P1.4 | High Anion Gap Acidosis | Na=145, Cl=98, HCO3=15 → AG=32, HAGMA | ☐ Pass ☐ Fail | |
| P1.5 | Corrected Calcium | Ca=8.5, Alb=3.0 → Corrected Ca=9.3 | ☐ Pass ☐ Fail | |
| P1.6 | eGFR Stage G5 (ESRD) | Cr=8.5, Age=70 → eGFR <15, ESRD flag | ☐ Pass ☐ Fail | |
| P1.7 | KB-8 Timeout Handling | Response within 5 seconds on timeout | ☐ Pass ☐ Fail | |

**Phase 1 Summary**: ___/7 tests passed

**Calculation Verification Notes**:
```
eGFR CKD-EPI 2021 Formula:
Female: 142 × min(SCr/0.7, 1)^-0.241 × max(SCr/0.7, 1)^-1.200 × 0.9938^age × 1.012
Male:   142 × min(SCr/0.9, 1)^-0.302 × max(SCr/0.9, 1)^-1.200 × 0.9938^age

Anion Gap = Na - (Cl + HCO3)
Normal: 8-12 mEq/L (without K), 10-14 mEq/L (with K)
Albumin-corrected: AG + 2.5 × (4.0 - albumin)
```

---

### Phase 2: Critical/Panic Value Detection

| Test ID | Analyte | Value | Expected Flag | Expected Response | Pass/Fail |
|---------|---------|-------|---------------|-------------------|-----------|
| P2.1 | Potassium | 4.2 mEq/L | NORMAL | No alert | ☐ Pass ☐ Fail |
| P2.2 | Potassium | 7.2 mEq/L | CRITICAL_HIGH | Panic alert, cardiac monitoring rec | ☐ Pass ☐ Fail |
| P2.3 | Potassium | 2.3 mEq/L | CRITICAL_LOW | Panic alert, arrhythmia risk | ☐ Pass ☐ Fail |
| P2.4 | Hemoglobin | 4.5 g/dL | CRITICAL_LOW | Panic alert, transfusion rec | ☐ Pass ☐ Fail |
| P2.5 | Glucose | 650 mg/dL | CRITICAL_HIGH | Panic alert, DKA/HHS workup | ☐ Pass ☐ Fail |
| P2.6 | Sodium | 118 mEq/L | CRITICAL_LOW | Panic alert, hyponatremia workup | ☐ Pass ☐ Fail |
| P2.7 | Troponin I | 0.15 ng/mL | HIGH | ACS workup recommended | ☐ Pass ☐ Fail |
| P2.8 | INR | 8.5 | CRITICAL_HIGH | Panic alert, bleeding risk | ☐ Pass ☐ Fail |
| P2.9 | Lactate | 8.5 mmol/L | CRITICAL_HIGH | Panic alert, sepsis/shock workup | ☐ Pass ☐ Fail |
| P2.10 | Platelets | 15,000/µL | CRITICAL_LOW | Panic alert, bleeding precautions | ☐ Pass ☐ Fail |

**Phase 2 Summary**: ___/10 tests passed

**Critical Value Reference Table**:
| Analyte | LOINC | Critical Low | Critical High | Source |
|---------|-------|--------------|---------------|--------|
| Potassium | 2823-3 | ≤2.5 mEq/L | ≥6.5 mEq/L | CAP |
| Sodium | 2951-2 | ≤120 mEq/L | ≥160 mEq/L | CAP |
| Glucose | 2345-7 | ≤40 mg/dL | ≥500 mg/dL | CAP |
| Hemoglobin | 718-7 | ≤5.0 g/dL | - | CAP |
| INR | 34714-6 | - | ≥8.0 | CAP |
| Lactate | 2524-7 | - | ≥7.0 mmol/L | CAP |
| Platelets | 777-3 | ≤20,000/µL | - | CAP |

---

### Phase 3: Panel-Level Pattern Recognition

| Test ID | Panel | Scenario | Expected Pattern | Pass/Fail |
|---------|-------|----------|------------------|-----------|
| P3.1 | BMP | Normal results | Normal panel, eGFR & AG from KB-8 | ☐ Pass ☐ Fail |
| P3.2 | BMP | DKA presentation | High Anion Gap Metabolic Acidosis | ☐ Pass ☐ Fail |
| P3.3 | CBC | Low all cell lines | Pancytopenia → Heme consult | ☐ Pass ☐ Fail |
| P3.4 | LFT | High AST/ALT, normal ALP | Hepatocellular injury (R>5) | ☐ Pass ☐ Fail |
| P3.5 | Renal | 3x baseline creatinine | AKI Stage 3 → Nephrology consult | ☐ Pass ☐ Fail |
| P3.6 | Thyroid | High TSH, Low T4 | Primary hypothyroidism | ☐ Pass ☐ Fail |

**Phase 3 Summary**: ___/6 tests passed

**Panel Pattern Verification**:
```
Liver Injury R-Ratio = (ALT/ULN_ALT) / (ALP/ULN_ALP)
R > 5: Hepatocellular
R < 2: Cholestatic
R 2-5: Mixed

AKI Staging (KDIGO):
Stage 1: 1.5-1.9x baseline OR ≥0.3 mg/dL increase
Stage 2: 2.0-2.9x baseline
Stage 3: ≥3.0x baseline OR Cr ≥4.0 OR initiation of RRT
```

---

### Phase 4: Context-Aware Interpretation

| Test ID | Context | Analyte/Value | Expected Adjustment | Pass/Fail |
|---------|---------|---------------|---------------------|-----------|
| P4.1 | Pregnancy (T2) | Hgb 10.5 g/dL | NORMAL (physiologic anemia) | ☐ Pass ☐ Fail |
| P4.2 | Pediatric (3yr) | WBC 12.0 10³/µL | NORMAL (age-adjusted) | ☐ Pass ☐ Fail |
| P4.3 | CKD Stage 4 | K 5.3 mEq/L | HIGH (not critical) | ☐ Pass ☐ Fail |
| P4.4 | Dialysis | Cr 8.5 mg/dL | eGFR N/A noted | ☐ Pass ☐ Fail |

**Phase 4 Summary**: ___/4 tests passed

**Context Adjustment References**:
| Context | Adjustment | Reference |
|---------|------------|-----------|
| Pregnancy T1 | Hgb 11-13 g/dL normal | ACOG |
| Pregnancy T2/T3 | Hgb 10-14 g/dL normal | ACOG |
| Pediatric (1-5yr) | WBC 6-17 10³/µL normal | Nelson Textbook |
| CKD Stage 4 | K up to 5.5 mEq/L tolerated | KDIGO |
| Dialysis | eGFR not applicable | KDIGO |

---

### Phase 5: Delta Check & Trending

| Test ID | Scenario | Expected Detection | Pass/Fail |
|---------|----------|-------------------|-----------|
| P5.1 | Hgb drop 12.0→8.5 in 24h | Delta check triggered, bleeding workup | ☐ Pass ☐ Fail |
| P5.2 | Creatinine trending up | WORSENING trajectory identified | ☐ Pass ☐ Fail |
| P5.3 | Baseline deviation | Baseline comparison with deviation % | ☐ Pass ☐ Fail |

**Phase 5 Summary**: ___/3 tests passed

**Delta Check Thresholds**:
| Analyte | Threshold | Window | Clinical Concern |
|---------|-----------|--------|------------------|
| Hemoglobin | >2 g/dL decrease | 24h | Acute bleeding |
| Creatinine | >50% increase | 48h | AKI |
| Platelets | >50% decrease | 24h | Consumption/destruction |
| Potassium | >1 mEq/L change | 24h | Rapid shift |
| Sodium | >8 mEq/L change | 24h | Osmotic demyelination risk |

---

### Phase 6: Care Gap Intelligence

| Test ID | Patient Profile | Expected Gap | Pass/Fail |
|---------|----------------|--------------|-----------|
| P6.1 | Diabetic, last HbA1c >6 months | HbA1c overdue alert | ☐ Pass ☐ Fail |
| P6.2 | On warfarin, last INR >30 days | INR monitoring gap | ☐ Pass ☐ Fail |

**Phase 6 Summary**: ___/2 tests passed

**Care Gap Monitoring Rules**:
| Condition/Medication | Lab Test | Frequency | Guideline |
|---------------------|----------|-----------|-----------|
| Diabetes | HbA1c | Q3 months | ADA |
| Warfarin | INR | Q4 weeks (stable) | CHEST |
| ACE-I/ARB initiation | Cr, K | 1-2 weeks | KDIGO |
| Metformin | eGFR | Q12 months | ADA |
| Lithium | Li level, TSH, Cr | Q3-6 months | APA |

---

### Phase 7: Governance & Safety

| Test ID | Test Description | Expected Outcome | Pass/Fail |
|---------|------------------|------------------|-----------|
| P7.1 | Critical value (K 7.5) | KB-14 task ID returned | ☐ Pass ☐ Fail |
| P7.2 | Any interpretation | Audit trail fields present | ☐ Pass ☐ Fail |

**Phase 7 Summary**: ___/2 tests passed

**Audit Trail Requirements**:
- [ ] Timestamp (ISO 8601)
- [ ] Request ID (UUID)
- [ ] Patient ID
- [ ] User/System ID
- [ ] Interpretation Version
- [ ] KB-8 calculation references

---

### Phase 8: Performance SLAs

| Test ID | Operation | SLA | Measured | Pass/Fail |
|---------|-----------|-----|----------|-----------|
| P8.1 | Single interpretation | <200ms | ___ms | ☐ Pass ☐ Fail |
| P8.2 | Panel assembly (BMP) | <500ms | ___ms | ☐ Pass ☐ Fail |
| P8.3 | Batch (10 results) | <1000ms | ___ms | ☐ Pass ☐ Fail |

**Phase 8 Summary**: ___/3 tests passed

---

### Phase 9: Clinical Edge Cases

| Test ID | Scenario | Expected Handling | Pass/Fail |
|---------|----------|-------------------|-----------|
| P9.1 | Hemolyzed specimen (K 6.8) | Hemolysis warning present | ☐ Pass ☐ Fail |
| P9.2 | Lipemic specimen (TG 850) | Lipemia interference noted | ☐ Pass ☐ Fail |
| P9.3 | Implausible value (K 15.0) | Implausible/verify warning | ☐ Pass ☐ Fail |

**Phase 9 Summary**: ___/3 tests passed

---

## OVERALL VALIDATION SUMMARY

| Phase | Tests | Passed | Failed | Status |
|-------|-------|--------|--------|--------|
| 1. KB-8 Dependency | 7 | ___ | ___ | ☐ PASS ☐ FAIL |
| 2. Critical Values | 10 | ___ | ___ | ☐ PASS ☐ FAIL |
| 3. Panel Patterns | 6 | ___ | ___ | ☐ PASS ☐ FAIL |
| 4. Context-Aware | 4 | ___ | ___ | ☐ PASS ☐ FAIL |
| 5. Delta/Trending | 3 | ___ | ___ | ☐ PASS ☐ FAIL |
| 6. Care Gaps | 2 | ___ | ___ | ☐ PASS ☐ FAIL |
| 7. Governance | 2 | ___ | ___ | ☐ PASS ☐ FAIL |
| 8. Performance | 3 | ___ | ___ | ☐ PASS ☐ FAIL |
| 9. Edge Cases | 3 | ___ | ___ | ☐ PASS ☐ FAIL |
| **TOTAL** | **40** | **___** | **___** | **☐ PASS ☐ FAIL** |

---

## CLINICAL SAFETY ASSESSMENT

### Risk Analysis Summary

| Risk Category | Mitigations Validated | Status |
|---------------|----------------------|--------|
| False Negative (missed critical) | Critical value detection accuracy ≥99% | ☐ Verified |
| False Positive (unnecessary alert) | Context-aware interpretation | ☐ Verified |
| Calculation Error | KB-8 formula validation | ☐ Verified |
| Data Integrity | Audit trail completeness | ☐ Verified |
| Latency Impact | Performance SLA compliance | ☐ Verified |

### Known Limitations

1. **Dependent on KB-8**: All calculated values (eGFR, Anion Gap) require KB-8 availability
2. **Reference Ranges**: Based on adult population; pediatric and geriatric adjustments applied contextually
3. **Specimen Quality**: System warns but cannot verify actual specimen condition
4. **Clinical Context**: Patient context must be provided for accurate interpretation

### Contraindications

- Not for standalone diagnostic use
- Requires licensed clinician review
- Not validated for research-only laboratory tests
- Critical values require immediate clinical verification

---

## APPROVAL SIGNATURES

### Clinical Validation Team

| Role | Name | Signature | Date |
|------|------|-----------|------|
| Lead Tester | _________________ | _________________ | _________ |
| QA Engineer | _________________ | _________________ | _________ |
| Clinical Specialist | _________________ | _________________ | _________ |

### Clinical Leadership Approval

**Chief Medical Officer (CMO) Review**

I, the undersigned, have reviewed the clinical validation test results for KB-16 Lab Interpretation & Trending Service and confirm:

☐ All critical value detection tests passed
☐ Panel pattern recognition meets clinical standards
☐ Context-aware interpretation is clinically appropriate
☐ Safety mitigations are adequate for intended use
☐ Known limitations are acceptable for deployment
☐ Performance meets clinical workflow requirements

**Clinical Assessment**:
```
_____________________________________________________________________________

_____________________________________________________________________________

_____________________________________________________________________________
```

**Recommendation**:
☐ **APPROVED** for clinical deployment
☐ **CONDITIONALLY APPROVED** with noted restrictions
☐ **NOT APPROVED** - requires remediation

| CMO Name | CMO Signature | Date |
|----------|---------------|------|
| _________________ | _________________ | _________ |

---

## APPENDIX A: Test Evidence Attachments

☐ Newman HTML Report attached (kb16-report-*.html)
☐ JSON Test Results attached (kb16-results-*.json)
☐ JUnit XML Results attached (kb16-junit-*.xml)
☐ Screenshot evidence for manual tests

---

## APPENDIX B: Change Log

| Version | Date | Changes | Approved By |
|---------|------|---------|-------------|
| 1.0 | _________ | Initial validation | _________ |

---

**Document Control**
- Storage Location: [Clinical Validation Repository]
- Retention Period: 10 years (per SaMD requirements)
- Access Control: Clinical Leadership, QA, Regulatory

---

*This document is part of the KB-16 Lab Interpretation Service Software Validation Package per IEC 62304 and FDA SaMD Guidance requirements.*
